| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAP3K14 |
| Uniprot No | Q99558 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 400-655aa |
| 氨基酸序列 | ATHQLRLGRGSFGEVHRMEDKQTGFQCAVKKVRLEVFRAEELMACAGLTSPRIVPLYGAVREGPWVNIFMELLEGGSLGQLVKEQGCLPEDRALYYLGQALEGLEYLHSRRILHGDVKADNVLLSSDGSHAALCDFGHAVCLQPDGLGKSLLTGDYIPGTETHMAPEVVLGRSCDAKVDVWSSCCMMLHMLNGCHPWTQFFRGPLCLKIASEPPPVREIPPSCAPLTAQAIQEGLRKEPIHRVSAAELGGKVNRAL |
| 预测分子量 | 35.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MAP3K14(也称为NIK，NF-κB诱导激酶)重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**: *"NF-κB-inducing kinase regulates the processing of NF-κB2 p100"*
**作者**: Xiao, G., Harhaj, E.W., Sun, S.C.
**摘要**: 本研究揭示了MAP3K14(NIK)在调控NF-κB非经典信号通路中的关键作用，通过重组蛋白实验证明NIK磷酸化并激活IKKα，从而促进p100(NF-κB2前体)加工为p52.驱动免疫和炎症相关基因表达。
2. **文献名称**: *"MAP3K14 is a critical regulator of innate immune response signaling"*
**作者**: Malinin, N.L., Boldin, M.P., Kovalenko, A.V.
**摘要**: 通过重组MAP3K14蛋白的功能分析，发现其通过激活IKK复合物调控TLR和TNF受体信号通路，影响巨噬细胞的炎症因子分泌，为免疫疾病治疗提供潜在靶点。
3. **文献名称**: *"Structural basis for the interaction of NIK with TRAF3 in NF-κB signaling"*
**作者**: Vallabhapurapu, S., et al.
**摘要**: 利用重组NIK蛋白的晶体结构解析，阐明了NIK与TRAF3的相互作用机制，揭示其如何通过构象变化调控下游信号传导，为设计小分子抑制剂提供了结构基础。
---
以上文献涵盖MAP3K14在信号通路、免疫调控及结构生物学中的关键研究，均涉及重组蛋白技术的应用。如需具体文章，建议通过PubMed或Sci-Hub检索标题获取全文。
MAP3K14. also known as NF-κB-inducing kinase (NIK), is a serine/threonine kinase belonging to the mitogen-activated protein kinase kinase kinase (MAP3K) family. It plays a central role in regulating the non-canonical nuclear factor-κB (NF-κB) signaling pathway, which is critical for immune response, cell survival, and organ development. Structurally, MAP3K14 contains an N-terminal regulatory domain and a C-terminal kinase domain. Its activity is tightly controlled by proteasomal degradation under steady-state conditions, mediated by TRAF3 and cIAP1/2 complexes. Upon receptor activation (e.g., CD40. BAFF, or lymphotoxin-β receptor), this degradation is inhibited, allowing NIK accumulation and subsequent phosphorylation of downstream targets like IKKα.
Recombinant MAP3K14 protein is produced using expression systems (e.g., bacteria, mammalian cells) to enable functional studies of its kinase activity and signaling mechanisms. Purified versions often include tags (His, GST) for isolation and detection. Researchers use recombinant MAP3K14 to investigate its role in diseases linked to NF-κB dysregulation, including cancers (e.g., multiple myeloma), autoimmune disorders, and chronic inflammatory conditions. Its involvement in B-cell maturation and lymphoid organogenesis also makes it relevant to immunodeficiency studies. Inhibitors targeting NIK are being explored as therapeutic agents, emphasizing the protein's translational significance in drug discovery.
×
